Focus: Mineralys is a public-stage small-molecule biotech focused on cardiovascular and nephrology indications, headquartered in Radnor, PA. The company is advancing lorundrostat across hypertension, chronic kidney disease, and obstructive sleep apnea.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Cooling — net -7 jobs in 30d
7 added, 14 removed. Slower than typical.
Mineralys is a clinical-stage biotech with near-term catalysts and public-market liquidity, but faces material cash runway and execution risk—suitable for risk-tolerant candidates seeking high-impact roles in a growing organization.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Mineralys Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Mineralys Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Mineralys Therapeutics (MLYS) Rule 144: Director sales and 2,170-share cashless exercise - Stock Titan
Mineralys Therapeutics (MLYS) Rule 144: Director sales and 2,170-share cashless exercise Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections Stock Titan
Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k - Stock Titan
Mineralys (MLYS) CEO sells 75,000 shares, still holds 705k Stock Titan
Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan - Stock Titan
Mineralys Therapeutics (MLYS) director trades 3,000 shares under plan Stock Titan
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress - Yahoo Finance
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress Yahoo Finance
Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares - Stock Titan
Mineralys Therapeutics (MLYS) files Form 144 to sell 75,000 shares Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo